Food and Drug Administration

Oncologic Drugs Advisory Committee

September 10, 2001


BLA 125019, Zevalin (ibritumomab tiuxetan) IDEC Pharmaceuticals Corporation

Clinical Trail Designs for First-line Hormonal Treatment of Metastatic Breast Cancer, Susan Honig, MD, Patricia Cortazar, MD, Rajeshwari Sridhara, PhD, FDA   ppt   htm

NDA 21-236 IntraDose (Cisplatin/Epinephrine Injectable Gel)


The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Cisplatin/Epinephrine Injectable Gel for the Treatment of Squamous Cell Carcinoma of the Head and Neck, Matrix Pharmaceutical, Inc.   ppt   htm

FDA Review:  Cisplatin/Epinephrine Gel (CEG) in the Treatment of Head and Neck Cancer, FDA   ppt   htm